Solventum — Third Quarter 2026 Earnings Summary
Solventum reported third-quarter 2026 sales of $1.9 billion, representing a 7.0% decrease on a reported basis and a 2.8% decline on an organic basis due to the reversal of advance orders placed prior to an ERP system cutover. The company adjusted its full-year adjusted earnings per share guidance upward to a range of $7.20 to $7.30 and expects full-year organic sales growth to reach the high end of the +2.5% to +3.0% range. GAAP diluted earnings per share for the quarter were $(0.07), while adjusted diluted earnings per share stood at $1.45, with operating cash flow reaching $177 million and free cash flow at $97 million. Additionally, Solventum has exited approximately 90% of its transition service agreements with 3M and completed its major ERP system cutovers.
- Company
- SOLVENTUM CORP
- Sector
- Healthcare
- Industry
- Health Information Services